





MAKE

The background is a blurred laboratory setting. On the left, there are shelves with various glassware and equipment. A bright light source is visible in the center-right background, creating a lens flare effect. The overall color palette is cool, with blues and greys.

Medicine.

A close-up photograph of a young child with dark hair and a bright smile, wearing a pink shirt with a white collar. The child is holding the hand of an adult wearing a green long-sleeved shirt. The background shows a weathered wooden door with peeling light blue paint. The text "we OPERATE on TRUST" is overlaid in white, bold, sans-serif font across the center of the image.

we OPERATE on TRUST



WE WORK FOR YOU



MAXWELL *LIFE SCIENCE PVT.LTD.*
Manufacturer & Exporter of Pharmaceutical Products



DIAGNOMAX

VictoNutras[®]
INVEST IN HEALTH WITH US



DAVAMAX



MAXWELL

Disclaimer

This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute prospectus or placement memorandum or an offer to acquire any securities. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date.

This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating Maxwell Life Science Private Limited future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. We undertakes no obligation to publicly revise any forward looking statements to reflect future likely events or circumstances.

This presentation cannot be copied and disseminated in any manner. No person is authorized to give any information or to make any representation not contained in and not consistent with this presentation and, if given or made, such information or representation must not be relied upon as having been authorized by or on behalf of the company. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Investor Presentation and Company Overview

www.mlspl.in



MAXWELL



WHO WE ARE:




MAXWELL

Maxwell Life Science is a trustworthy and well-known name among Indian Pharmaceutical formulations manufacturing businesses, committed to serving humanity for the long term. We began in 2004 and we had a clear vision of making an impact in pharmaceutical industry by providing premium quality generic drugs at affordable prices.

We are an **ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and GMP Certified** Ethical Pharmaceutical Company with our cutting-edge manufacturing facilities being strategically located in Boisar, Maharashtra; providing us logistic advantage.

Our company has marked in India and international markets.

We have been exporting to **27** Countries in Africa, North America, South America, Southeast Asia and MENA regions





MAXWELL

OUR VISION

Our vision is to enhance accessibility to high-quality healthcare solutions for every individual. By seamlessly integrating online and offline channels through our user-friendly application, we strive to make healthcare products and services readily available to consumers across the nation.



MAXWELL

OUR MANUFACTURING CAPABILITIES:

Working hard from the start, we have earned a reputation in the industry for producing quality and safe products such as:

• **Antibacterial** • **Antimalarial** • **Anti-fungal** • **Antacids** • **Anti-Ulcers** • **Impotence drugs** • **Anti-Amoebic**



Tablets



Capsules



Powders



Syrups



Pellets



Ointments

INVESTMENT HIGHLIGHTS:

01

Industrial Expertise

With 30+ years of experience, we provide cutting-edge, cost-effective pharmaceutical products, prioritizing product quality and client services. We leverage goodwill that our brands holds in the minds of our customers and in the marketplace.

- ✓ State of the Art Manufacturing Facility
- ✓ Skilled manpower with 100+ core employees

02

Scalable and Growing

We are one of the fastest Growing organizations in Pharma Industry. We possesses the potential of introducing new molecules to enter new segments. We have differential plans like contractual manufacturing, partnerships, etc.

- ✓ Complete hygiene is practiced by experts
- ✓ Manufacturing process under the surveillance

03

Diverse clients /products

We cater more than 250 different types of formulations in Liquid orals, ointments, tablets, capsules, injectables & pellets. We have set a new vision to take Maxwell Life Science Private Limited to more than 50 countries which is currently at 27 countries.

- ✓ Soundly connected marketing partners, Institutional clients and distribution network

04

Operational efficiency

Since 2004 we have been providing premium quality generic drugs efficiently and with restless force of enthusiasm, dedication, hard work and co-operation of all those who are associated, which leads the organization achieve its operational efficiency and growth goals.

PRODUCTIONS AND FORMULATIONS:



MAXWELL

Tablets

Antipsychotic
Antagonists
Antiulcer
(ACE) Inhibitors
Beta Blockers
Antacid
Benzodiazepines
Anthelmintics
Bronchodilators
Antiarrhythmics
Cardiac
Glycosides
Antibiotics
Corticosteroids
Anticonvulsant
Digestive Enzyme
Antispasmodics
Diuretics
Antifungal
Cartilage
Antilipidemic
Antihistaminic

Antimalarial
Multivitamin &
Antimuscarinic
Multimineral
Antidepressant
& More

Capsules

Antibiotics
Anticold
Anticonvulsants
Antidiarrhoeals
Antifungal Centrally
acting
Analgesic
GERD
Multivitamin
Multiminerals
NSAID
/Antipyretic
/Antiinflammatory
& more

Oral Liquids

Carminative
Antacid
Amoebiasis
Anthelmintics
Antiallergic
Antidiarrhoeals
Antifungal
Analgesic
Antibiotic
Antihistamine
Antifungal
Antitussives
Expectorants

Ointments

Anti-acne
Antibacterial
Antimicrobial
Antiseptic
Antiviral Erectile
dysfunction
Corticosteroid
Local
anaesthetics
Sanitizer
NSAID/Topical
Analgesics

Pellets

Antibiotics
Anticold
Antiallergic
Antifungal
Centrally acting
Analgesic
GERD
Analgesic
Haematinics
Supplements
Anti-
inflammatory
Multivitamins

Powders

Energy Drink
Antipyretic,
Anticold &
decongestant
Erectile
Dysfunction
Oral
rehydration
Salt

INDIAN PHARMACEUTICAL INDUSTRY:



MAXWELL


National Pharmaceutical Policy (2023):

Aligned with Vision 2047, the policy is being drafted to serve as a comprehensive framework to address the challenges faced by Indian Pharmaceutical industries and provide definitive policy interventions to enhance the collective ecosystem.

2047

The Draft Policy

It encompasses five key pillars: Fostering Global Pharmaceutical Leadership, Promoting Self-Reliance, Advancing Health Equity and accessibility, Enhancing Regulatory Efficiency in the Indian Pharmaceutical Sector and Attracting investments.



The Pharma sector currently contributes to around 1.72% of the country's GDP.

The Pharmaceutical industry in India is 14th largest in terms of value.

14th



Generic Medicine

Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume.

PRODUCTION GROWTH CHART:





MAXWELL



■ Production Capacity

■ Installed Capacity



OUR COMPETITIVE STRENGTH:



We are a trusted brand. We are a supplier to numerous renowned Pharma companies and Institutions.



Our Customers are globally spread. We are ready to export to more than 50 countries and currently we have our presences at 27 countries.



Comprehensive pharma portfolio for diverse customers. Also we cater to changing and specific need-based requirements.



Well experienced management team with extensive experience in Pharma Industry as well as marketing.



Technology backed infrastructure to support new & innovative products and sustainable solutions.



Quality Assurance by well defined quality and standard safety procedures & protocols.

India Presence
6 States



Staff Strength
100



Countries Reach
27 Countries



30 + Years of Industrial Experience

MANUFACTURING STANDARDS, CERTIFICATIONS AND R&D.



MAXWELL

Strong product development and process optimization capabilities

Our business is attributable to our strong product development capabilities, which have enabled us to manufacture key more than 50 pharmaceutical products with higher realization and profitability.

We continuously invest in R&D with a focus on sustainability




Our R&D department works towards product development, quality enhancement, operational efficiency and scale-up productivity.

Manufacturing Facility with regulatory accreditations

We hold cGMP (Good Manufacturing Process) approval. We abide by various set norms as per Guideline of ISO 9001:2015, ISO 14001:2015 & ISO 45001:2018. In order to effectively follow norms prescribed by our clients Manufacturing facility is as per WHO set standards.

Our Manufacturing process is contamination free

Complete hygiene is practiced by experts and steps are taken that our teams are medically fit. Pre and post manufacturing process are conducted under the surveillance of experts.





MAXWELL

OUR INFRASTRUCTURE




MAXWELL LIFE SCIENCE PVT. LTD.

GATE NO. 2



MAXWELL

ADVANTAGE IN INDIA



- India is one of the biggest suppliers of low-cost and high quality, medicines in the world. (30%-35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets)
- Indian medicines are preferred in all parts of the world
- India has been traditionally quite strong and called as a pharmacy of the world.
- The largest number of FDA- approved plants outside the US is in India.
- Skill availability and low employee cost.





Key Growth drivers.

- Increased investments: Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects.
- Favorable Government initiatives and policies.
- Chronic therapies such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, are on the rise.
- Heavy investment globally for new medicines especially lifesaving drugs, and thrust on rural health programs.
- To achieve self-reliance and minimise import dependency in essential bulk drugs
- Healthcare and Insurance boost in tier 2 and tier 3 cities.

BREAK-UP OF THE REVENUE AND GROWTH WAY FORWARD



MAXWELL



Product Expansions



Strategic Partnerships



Process and System Approach



Institutional client relations

- We have a strong presence in 6 States while our current target is for 10 states.
- We are strengthening our position across India through product expansion, constant increase in government sales etc.
- In India we plan to collaborate with institutions such as private hospitals, Distributors and pharmaceutical companies to enable pan India expansions
- Leveraging our client relationship, extending new regions in India and new countries for more business.
- Registering more formulations with existing export countries.
- Explore Marketing agency in exporting and new countries for an easy entrance.
- Overall strengthening presences through product expansions.

FOCUSING ON INSTITUTIONAL CLIENTS



MAXWELL

Importance of Institutional Clients

The public health market is made up of different segments, with some that are more attractive and strategic.

State hospitals medicine purchases is one of the important spend of government in health sector especially in tier 1 and tier 2 cities.

However, this segment is relatively inaccessible for established players due to low price levels and the fragmented nature of procurement.

This segment's importance lies not in its price, but in its size and also its ability to provide access to key opinion leaders (KOLs) through sponsored research and efforts at designing treatment protocols.



OUR MANAGEMENT



MAXWELL

Chairman and Managing Director

Sanjay Surana is renowned for his commitment to excellence, innovation, and leadership. With a strong foundation in the pharmaceutical industry, he has successfully transitioned from technical roles to entrepreneurship, establishing and leading companies that prioritize quality and customer satisfaction. His vision is to continue driving growth, innovation, and positive impact within the healthcare sector.

Total Experience of 30 years



Mr. Sanjay Surana



Mrs. Neetu Surana

Executive Director

Neetu S Surana has been instrumental in supporting the growth of the company by undertaking responsibility of the Administration activities. Her strategic acumen extends to a deep understanding of the company's strengths and financial aspects, contributing to Maxwell Life Science Pvt Ltd's sustained success in the dynamic pharmaceutical sector.

Total Experience of 9 years

CORPORATE GOVERNANCE



MAXWELL



Mr. Piyush Trivedi

Independent Director

Experienced professional in Finance , Consulting and Strategy with almost three decades of experience in Fund raising , Process Improvement, and Strategic Consulting Space. Piyush Trivedi brings with him the focus and experience on Fund Raising , Corporate Planning and Corporate Governance in order to support Maxwell in its High Growth Trajectory. He has a keen understanding of Market dynamics, Regulatory aspects, Business requirements for high growth and ensuring sustainability of Business.



Mr. Vijaykumar Singhavi

Independent Director

Distinguished pharmaceutical professional with exceptional academic achievements and a remarkable career in regulatory compliance and drug inspection. Graduating as a Gold Medalist in Bachelor of Pharmacy from Nagpur University, demonstrated outstanding academic excellence early in their career. Throughout their tenure at FDA Maharashtra, held various positions, starting as a Drug Inspector and rising to the rank of Technical Officer (Allopathic Drugs). Their contributions were further recognized by being appointed as an Officer on Special Duty with the Honorable Minister of FDA.



Mr. Rajendra Runwal

Independent Director

Mr. Runwal's value extended beyond his official duties, as his strong networking skills allowed him to forge meaningful connections within the Food, Nutraceutical, and Health Supplement industries. He played a pivotal role in providing support for Food Safety Management Systems (FSMS), evaluating licenses, offering strategic advice on food category selection, and ensuring establishments' compliance and audit readiness for various regulatory acts. His comprehensive approach to his responsibilities and his proactive contributions to industry advancement highlight Mr. Runwal's significant impact and legacy in the realm of food sciences and regulatory affairs. 18

MEET OUR TEAM



Mr. Sunil Vasaikar

Chief Financial Officer (CFO)

Total Experience: 29 years



Mr. Pravin Amin

Sr. Plant Manager

Total Experience: 32 years



Mr. Milind Sawarkar

Production Manager

Total Experience: 20 years



Mr. Manohar Salunkhe

Manager Regulatory Affairs

Total Experience: 20 years



Mr. Manoj Kadu

Manager QA/QC

Total Experience: 17 years



Ms. Namrata Mohite

QA Incharge

Total Experience: 10 years



Ms. Amruta Sankhe

QC Incharge

Total Experience: 9 years



Mr. Kalpesh More

Manager Logistics

Total Experience: 20 years

“ We have experts who are professional in their fields, and all of them will put forth great effort to provide the best service for you. ”

KEY MILESTONES:



MAXWELL

Our Company proudly announces its entry into the international export market, making a significant milestone in our growth journey..

Overseas Expansion

2004

Registration

In 2004, our company registered as a Private limited company under the Companies Act, 1956.

2007

2015

WHO Certification

Our company has successfully attained the World Health Organisation (WHO) certification. This certification marks a pivotal moment in our journey, reflecting our unwavering commitment to upholding the highest standards of quality, safety and efficacy in our products

Our company has successfully secured a series of Government tenders from various states authorities, marking a significant milestone in our growth trajectory. By winning these tenders, we solidify our position as a trusted partner for government agencies, showcasing our commitment to delivering excellence and value in every project we undertake.

Institutional clients

2022



OUR DOMESTIC AND GLOBAL PRESENCE




MAXWELL

Our Global Presence

Nigeria	Cameroon
Cambodia	Guinea
Kenya	Mali
Ghana	Dakar
Tanzania	Kano
Ethiopia	Burkina
Uganda	Faso Lome
Zambia	Matadi
Mozambique	Senegal
Congo	Philippines
Sierra Leone	Panama
Liberia	Brazil
Myanmar	Honduras
Ivory Coast	

Our India Presence

Maharashtra	West Bengal
Rajasthan	Tamil Nadu
Uttar Pradesh	
Bihar	



PROFIT AND LOSS PROJECTION



MAXWELL

PARTICULARS	INR		Crs			
	Audited	Audited	Audited	Provisional	Projection	Projection
	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26
Operating Statement						
1 i. Domestic Sale	8.24	11.09	33.18	77.72	115.13	166.56
ii. Export Sale	9.98	17.44	13.38	1.91	30.00	75.00
iii. Sale of Service	0.00	0.00	0.00	2.07	4.50	7.50
iv. Sale of Services - Export Benefit	0.00	0.00	0.00	0.02	0.38	0.94
1 Total Gross Sales	18.22	28.53	46.57	81.72	150.00	250.00
2 Less: Excise Duty						
3 Total Income	18.22	28.53	46.57	81.72	150.00	250.00
4 Growth in sales	0%	57%	63%	75%	84%	67%
Cost of Sales						
5 a. Raw Material (Imported)						
b. Raw Material (Indigenous)	6.00	12.67	33.68	66.29	105.69	177.00
c. Stores & Spares (Imported)	0.00	0.00	0.00	0.00	0.00	0.00
d. Stores & Spares (Indigenous)	0.10	0.15	0.23	0.28	0.74	1.24
6 Power & Fuel	0.77	0.80	0.81	0.82	2.11	3.54
7 Direct Labour	3.56	2.63	1.02	1.09	3.17	5.31
8 Repairs and maintainance	0.19	0.18	0.14	0.12	2.11	3.54
9 Other Mfg. Expenses	0.05	0.05	0.00	0.00	0.42	0.71
10 Depreciation	0.80	0.80	0.67	0.68	1.89	4.13
11 Others expenses	5.84	5.42	5.41	0.52	1.85	3.10
a Purchase of Traded Goods	0.01	0.00	0.00	0.00	0.00	0.00
b Packing and Forwarding expenses	5.16	4.85	5.08	0.52	1.06	1.77
c Transport Expenses	0.67	0.57	0.33	0.00	0.79	1.33
d						
Sub Total	17.29	22.70	41.96	69.80	118.00	198.56

PARTICULARS	INR		Crs			
	Audited	Audited	Audited	Provisional	Projection	Projection
	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26
Operating Statement						
12 Add: Opening Stock in Process	3.74	4.87	2.60	4.49	6.45	12.00
Sub Total	21.03	27.57	44.56	74.29	124.45	210.56
13 Deduct : Closing Stock in Process	4.87	2.60	4.49	6.45	12.00	21.25
Cost of Production	16.16	24.96	40.07	67.84	112.45	189.31
14 Add: Opening Stock of Finished Goods					0.00	
Sub Total	16.16	24.96	40.07	67.84	112.45	189.31
15 Deduct : Closing Stock OF Finished Goods						
Sub Total (Total Cost of Sales)	16.16	24.96	40.07	67.84	112.45	189.31
16 Gross profit	2.06	3.57	6.50	13.88	37.55	60.69
Gross Profit/ Sales	11.29%	12.51%	13.95%	16.98%	25.04%	24.28%
17 Selling Expenses	0.00	0.00	0.07	0.01	0.75	1.25
18 Administrative Expenses	0.68	1.98	4.42	5.61	10.48	16.38
Sub Total	16.84	26.94	44.56	73.46	123.68	206.94
19 Operating Profit before interest	1.37	1.59	2.00	8.25	26.32	43.06
a. Interest on CC.	1.30	1.38	1.35	1.35	1.93	1.70
b. Interest on TL	0.14	0.12	0.22	0.11	0.57	0.71
c. Other interests	0.00	0.00	0.00	0.85	0.00	0.00
20 Total Interest	1.45	1.50	1.57	2.32	2.49	2.41
21 Operating Profit after Interest	-0.07	0.09	0.43	5.93	23.83	40.64
22 Add: Other non operating Income						
a Interest/Dividend/Royalties etc..	0.19	0.65	0.01	0.02	0.00	0.00
b Other Income	0.00	0.00	0.55	0.12	0.25	0.25
c						
d						
Sub Total	0.19	0.65	0.56	0.14	0.25	0.25
23 Deduct other non operating expenses						
a Interest/Dividend/Royalties etc..						
b Capital raise expenses						
c Intangibles written off -1						
d Other Financial Charges						
e Processing fees (CC Limit)						
Sub Total	0.00	0.00	0.00	0.00	0.00	0.00
Net of other non operating						
24 Income/Expenses	0.19	0.65	0.56	0.14	0.25	0.25
25 Profit before Tax /Loss (PBT)	0.12	0.74	0.99	6.07	24.08	40.89
26 Provision for Taxes	0.06	0.24	0.24	2.14	6.06	10.29
27 Net Profit/Loss (PAT)	0.05	0.50	0.75	3.94	18.02	30.60

BALANCE SHEET



MAXWELL

PARTICULARS						
	INR		Crs			
	Audited	Audited	Audited	Provisional	Projection	Projection
Years	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26
Operating months	12	12	12	12	12	12
LIABILITIES						
Current Liabilities						
Short Term loans from Applicant Bank						
1 including BP, BD & PCFC	13.76	13.54	13.52	13.79	22.00	17.00
Short Term loans From Other banks						
including BP & BD						
Sub Total (A)	13.76	13.54	13.52	13.79	22.00	17.00
2 Short Term Borrowings from Others						
3 Sundry Creditors (Trade)	2.28	7.48	30.03	22.28	16.88	28.12
4 Advance Payment from Customers	0.57	1.92	2.13	3.41	4.50	15.00
5 Net Provision for Taxation (if positive)	0.00	0.00	0.29	1.70	6.07	10.29
6 Dividend Payable	0.00	0.00	0.00	0.00	0.00	0.00
7 Other Statutory Liab. (Due within one Year)	0.02	0.03	0.07	0.43	0.00	0.00
8 Overdue Term Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Installments of term Loan/ DPGs/ Deposits/ debentures due within next						
9 year	0.11	0.21	0.27	3.02	1.18	1.29
Other Current Liabilities & Provisions						
10 (due with in one year)	0.56	0.79	0.63	1.07	1.93	2.68
a Expenses Payable	0.56	0.79	0.58	0.00	1.13	1.88
b Other current Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
c Provision for Others	0.00	0.00	0.00	0.88	0.80	0.00
d Other debt due within one year	0.00	0.00	0.05	0.19	0.00	0.00
11 Sub Total (B)	3.55	10.44	33.41	31.91	30.56	57.38
12 TOTAL CURRENT LIABILITIES	17.31	23.98	46.93	45.69	52.56	74.38
TERM LIABILITIES						
13 Debentures (not maturing within one Year)						
14 Preference Shares (redeemable after 1 year)						
14 Term Loan from Bank(Less next Year Instalments)	1.05	0.90	0.75	1.20	7.39	6.10
Term Loan from Other Banks/Inst.(Ecl.						
14 Instal.due next Yr.)	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Payments Credits (Ecl.						
15 Instal.due next Yr.)	0.00	0.00	0.00	0.00	0.00	0.00
16 Term deposits (Ecl. Instal.due next Yr.)	0.00	0.00	0.00	0.00	0.00	0.00
17 Other term Liabilities	7.75	7.11	1.21	2.02	0.20	0.20
a Unsecured Loans	7.75	6.85	0.00	0.00	0.00	0.00
b Unsecured Loans from Banks/FI's	0.00	0.26	1.21	1.82	0.00	0.00
c Other liability	0.00	0.00	0.00	0.20	0.20	0.00
18 TOTAL TERM LIABILITIES	8.80	8.01	1.96	3.22	7.59	6.30
19 TOTAL OF OUTSIDE LIABILITIES	26.11	31.99	48.89	48.91	60.14	80.68
NET WORTH						
20 Share Capital & Premium	4.11	4.11	4.11	4.11	54.11	54.11
21 General Reserve						
22 Revaluation Reserve						
23 Accumulated Profit & Loss Balance	2.13	2.18	2.68	3.42	7.35	25.37
24 Other reserves (excluding Provisions)						
25 Others	0.15	0.15	0.15	0.37	0.37	0.37
a Deferred tax liability	0.00	0.00	0.00	0.22	0.22	0.22
b Share application money	0.00	0.00	0.00	0.00	0.00	0.00
c Premium of issues of shares	0.00	0.00	0.00	0.00	0.00	0.00
d Capital Subsidy from SIDBI	0.15	0.15	0.15	0.15	0.15	0.15
26 Surplus (+) or deficit (-) in Profit & Loss a/c	0.05	0.50	0.74	3.93	18.02	30.60
27 NET WORTH	6.44	6.94	7.68	11.83	79.85	110.46
28 TOTAL LIABILITIES (18+24)	32.54	38.93	56.57	60.75	140.00	191.14


PARTICULARS						
	INR		Crs			
	Audited	Audited	Audited	Provisional	Projection	Projection
Years	2020-21	2021-22	2022-23	2023-24	2024-25	2025-26
Operating months	12	12	12	12	12	12
ASSETS						
Current Assets						
1 Cash & Bank Balances	0.05	0.01	0.01	0.03	7.05	16.86
2 Govt. & other Trustee securities						
3 Fixed Deposits with Banks						
4 Domestic Receivables including BP/BD	3.68	8.42	19.10	30.35	20.54	26.93
5 Export Receivables including BP/BD)	8.14	7.98	0.00	0.00	4.46	10.50
6 Deferred receivables(due within one year)	0.00	0.00	0.86	0.19	0.00	0.00
7 Refund Dues from Government Authorities	0.00	0.00	0.00	0.92	0.00	0.00
8 Indigenous Rawmaterial	3.75	8.64	13.72	12.69	19.50	27.50
9 Stock in Process	4.87	2.60	4.49	6.45	12.00	21.25
10 Finished Goods	0.00	0.00	0.00	0.00	0.00	0.00
11 imported Consumables	0.00	0.00	0.00	0.00	0.00	0.00
12 Indigenous consumables	0.00	0.00	0.00	0.00	0.00	0.00
a. Packing Material	0.00	0.00	0.00	0.00	0.00	0.00
13 Advances to Suppliers	0.27	0.21	1.12	0.88	20.25	12.95
14 Net Advance Payment of Taxes (if positive)	0.00	0.00	0.00	0.00	6.06	10.29
15 Other Current Assets (specify major items)	4.90	3.85	4.87	0.72	2.95	3.98
a Balance with Authorities	2.18	3.66	4.37	0.00	2.30	3.33
b Other Advances	2.59	0.12	0.14	0.06	0.15	0.15
c Deposits-EMD & Fixed Deposits	0.00	0.00	0.00	0.00	0.00	0.00
d Vat Credit Recievable	0.03	0.00	0.00	0.00	0.00	0.00
e Prepaid Expenses	0.09	0.08	0.35	0.66	0.50	0.50
16 TOTAL CURRENT ASSETS	25.66	31.71	44.18	52.23	92.80	130.27
FIXED ASSETS						
17 Gross Block (Land & Building Machinery	14.02	14.02	14.68	15.07	16.79	50.79
18 Add Capital expenditure	0.00	0.66	0.39	1.72	34.00	24.00
19 Depreciation to Date	7.79	8.59	9.25	9.94	12.44	17.71
20 Net Block	6.24	6.10	5.82	6.86	38.35	57.08
OTHER NON CURRENT ASSETS						
a Investments in Sub. cos./ affiliates	0.00	0.00	0.00	0.00	0.00	0.00
b Investment in Others	0.01	0.01	0.05	0.05	0.05	0.05
c Capital Advances	0.00	0.00	0.33	1.00	1.00	0.00
d Deferred Receivables(Maturng after a year)	0.00	0.00	5.36	0.00	0.00	0.00
e Security Deposits	0.00	0.00	0.36	0.18	0.18	0.18
f Non Consumable Stores & Spares	0.00	0.00	0.00	0.00	0.00	0.00
g Long outstanding dues & Other non Current						
h Deferred Tax Asset (net)	0.29	0.27	0.28	0.00	0.00	0.00
i Long Term Loans & Advances	0.31	0.82	0.19	0.00	0.00	0.00
j Fixed Deposits more than 1 Year	0.00	0.00	0.00	0.43	3.43	0.43
TOTAL OTHER NON CURRENT ASSETS	0.61	1.10	6.57	1.66	4.66	0.66
Intangible Assets						
a Preliminary Expenses	0.04	0.02	0.00	0.00	0.00	0.00
b Deferred Revenue expenditures	0.00	0.00	0.00	0.00	0.00	0.00
c Other Intangibles (patents, goodwill, etc.)	0.00	0.00	0.00	0.00	0.00	0.00
d Preliminary Expenses	0.00	0.00	0.00	0.00	4.16	3.12
e						
22 Total Intangible Assets	0.04	0.02	0.00	0.00	4.16	3.12
23 Total Assets	32.55	38.93	56.57	60.75	139.98	191.13
24 TOTAL ASSETS	32.55	38.93	56.57	60.75	139.98	191.13

KEY RATIOS




MAXWELL


Revenue (in Crore)




Gross Profit (in Crore)




Net Profit (in Crore)




Growth in Sales Y-o-Y



Gross Profit/Sales







Net Profit/Sales



KEY RATIOS



MAXWELL



Maxwell Life Science: Pioneering the Future of Healthcare



MAXWELL



OUR BRAND AND MARKET EXPANSION STRATEGY FOR FUTURE



Under the banner of **DAVAMAX**, we will introduce a diverse range of pharmaceutical products, ensuring efficacy and affordability. This brand will symbolize trust, reliability, and excellence in healthcare.



Additionally, under the banner of **DIAGNOMAX**, we will forge strategic partnerships with diagnostic centers and hospitals, offering comprehensive health check-up services. As we progress, our aim is to establish our own network of diagnostic centers and hospitals, further strengthening our presence in the healthcare sector.

Through a multi-faceted approach, we plan to expand our market presence and reach. Our online platform will cater to the growing demand for convenient healthcare solutions, while our offline channels will establish a physical presence in key locations nationwide.

KEY ADVANTAGES

01

Innovative Technology: Our user-friendly application will streamline the purchasing process, enhancing customer experience.

02


Diverse Product Portfolio: From branded to generic products, we offer a comprehensive range to meet varied healthcare needs.

03

Vertical Integration: By owning manufacturing facilities and healthcare centers, we ensure quality control and seamless service delivery.

04

Investment Opportunity: Maxwell Life Science presents a unique investment opportunity in the burgeoning healthcare sector. With a solid foundation in manufacturing, marketing, and service provision, we are poised for exponential growth and value creation.



Conclusion: Join us in our journey to redefine healthcare delivery in the domestic market. Maxwell Life Science is not just a company; it's a commitment to better health and a brighter future for all.



MAXWELL

Thank You

Corporate Office

Shop No. 5, 2nd Floor,
Target Mall, Near Saraswat Bank,
Chandavarkar Road, Borivali West,
Mumbai -400 092, INDIA

Factory Office

T-53 & T-81, M.I.D.C.,
Tarapur Boisar,
Palghar-401 506 India,
Email: info@mlspl.in
Tel. (02525) 661297, +91 93200
09232/34

www.mlspl.in

